BCL9 and colorectal cancer: Tanton et al. investigated clinical target therapies for Wnt/β-catenin signaling, exploring a novel β-catenin/BCL9 complex inhibitor that can block oncogenic Wnt signaling and disrupt cholesterol homeostasis in colorectal cancer (Tanton et al., 2022).